[A22-13] Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2022
Project no.:
A22-13
Commission:
Commission awarded on 02.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least 2 prior therapies
Result of dossier assessment:
- Patients who have not yet received a BTK inhibitor and/or a BCL-2 inhibitor: added benefit not proven.
- Patients after prior therapy with at least one BTK inhibitor: added benefit not proven.
- Patients after prior therapy with at least one BCL-2 inhibitor: added benefit not proven.
- Patients after prior therapy with at least one BTK inhibitor and one BCL-2 inhibitor: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-14 | Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |